Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386011 | PMC |
| http://dx.doi.org/10.1016/j.bas.2024.102921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[RIGHT HEART FAILURE PRESENTATION OF IDIOPATHIC MASSIVE PULMONARY EMBOLISM - CASE REPORT].
Harefuah
December 2024
Internal Medicine F Department, Wolfson UMC Holon.
Massive pulmonary embolism (PE) is a life threatening condition with age-related escalation in prevalence. Acute PE is a common and sometimes fatal disease. The approach to the evaluation should be efficient while simultaneously avoiding the risks of unnecessary testing so that therapy can be promptly initiated and potential morbidity and mortality avoided.
View Article and Find Full Text PDFReal world application of the 2023 ACR/EULAR antiphospholipid antibody syndrome classification criteria in a pharmacist directed anticoagulation clinic.
Lupus
January 2025
Department of Pharmacy, Upstate University Hospital, Syracuse, NY, USA.
Article Synopsis
- - The study aimed to assess how many patients with antiphospholipid antibody syndrome (APS) met the new 2023 ACR/EULAR classification criteria and to explore reasons for those who did not qualify.
- - A review of 51 patient records revealed that only 12 (23.5%) met the classification criteria, while 33 (64.7%) did not, with various reasons cited including failure to meet laboratory or clinical standards.
- - Findings suggest APS diagnosis and classification are complex, highlighting a need for further evaluation and management strategies for the small number of patients who still fit the new criteria.
Mechanical Viability and Functionality Assessment of a New Sutureless Endoluminal Microvascular Device: A Preliminary In Vivo Rabbit Study.
J Med Device
March 2025
Patient Experience Program, Consorci Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona 08036, Spain.
Our group has developed a new nitinol endoluminal self-expandable device for microvascular anastomosis. It attaches to each vessel ending with opposite directed microspikes and reaches complete expansion at body temperature, using the nitinol shape memory capacity. The main purpose of this first in vivo trial is to evaluate the mechanical viability of the device and its immediate and early functionality.
View Article and Find Full Text PDFImipramine in dogs: A pharmacokinetic study following oral administration under fasted and fed conditions.
Vet J
December 2024
Department of Veterinary Sciences, University of Pisa, Viale delle Piagge, 2, Pisa 56124, Italy; Department of Veterinary Medicine, University of Sassari, Via Vienna, 2, Sassari 07100, Italy. Electronic address:
This study investigates the pharmacokinetics (PK) of imipramine, a tricyclic antidepressant used in human psychiatric disorders and increasingly considered in veterinary medicine. Despite its longstanding use in canines, prior research on imipramine's PK in dogs is lacking. This study aimed to determine the PK of imipramine in dogs in regards to feeding conditions, and to ascertain whether desipramine (active metabolite) is formed or not.
View Article and Find Full Text PDFReevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit.
Clin Neurol Neurosurg
November 2024
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Background: Heparin may be administered during mechanical thrombectomy (MT) for acute ischemic stroke due to large vessel occlusions (AIS-LVO), with the aim of enhancing reperfusion and improving patient outcomes. The uncertain balance between risks and benefits of administering heparin during MT prompted us to perform this systematic review and meta-analysis.
Methods: A comprehensive search was conducted in PubMed, Embase, and Scopus to find studies that report the safety or efficacy of administering heparin during MT for AIS-LVO.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!